Open | $2.790 |
Close | $2.700 |
Volume / Avg. | 40.868K / 124.305K |
Day Range | 2.661 - 2.850 |
52 Wk Range | 1.550 - 13.490 |
Market Cap | $18.882M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 27 |
Short Interest | 0.58% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Minerva Neurosciences (NASDAQ: NERV) through any online brokerage.
Other companies in Minerva Neurosciences’s space includes: Galecto (NASDAQ:GLTO), Immuron (NASDAQ:IMRN), T2 Biosystems (NASDAQ:TTOO), Lumos Pharma (NASDAQ:LUMO) and NuCana (NASDAQ:NCNA).
The latest price target for Minerva Neurosciences (NASDAQ: NERV) was reported by HC Wainwright & Co. on Tuesday, February 27, 2024. The analyst firm set a price target for 11.00 expecting NERV to rise to within 12 months (a possible 307.41% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Minerva Neurosciences (NASDAQ: NERV) is $2.7 last updated March 18, 2024 at 5:18 PM EDT.
There are no upcoming dividends for Minerva Neurosciences.
Minerva Neurosciences’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Minerva Neurosciences.
Minerva Neurosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.